B. Riley Securities Sticks to Their Buy Rating for Harrow Health (HROW)
I'm PortAI, I can summarize articles.
According to TipRanks, Mamtani is an analyst with an average return of -4.4% and a 33.33% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Agenus, and Cytokinetics. In addition to B. Riley Securities, Harrow Health also received a Buy from Craig-Hallum’s Chase Knickerbocker in a report issued today. However, on September 16, TR | OpenAI – 4o reiterated a Hold rating on Harrow Health (NASDAQ: HROW).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments